Assembly Biosciences Q1 2025 net loss $8.8M; cash $91M; pipeline data expected in 2025

ASSEMBLY BIOSCIENCES, INC.

2025-Q1 EPS reported -$1.17 revenue$9,419,000

Net loss $8.8M ($1.17/diluted share) vs $9.1M in Q1 2024; revenue from Gilead collaboration $9.4M (up from $5.8M).
Cash, equivalents and marketable securities $91.0M as of March 31, 2025; projected to fund operations into mid-2026.
R&D expenses $14.9M (up from $11.9M) driven by ABI-6250 and ABI-5366; G&A $4.5M (slight decrease from $4.6M).
Interim Phase 1b data for HSV candidates ABI-5366 and ABI-1179 expected in fall 2025; Phase 1a data for HDV candidate ABI-6250 in Q3 2025.
Phase 1b data for HBV candidate ABI-4334 (400 mg cohort) expected in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.